Aeterna Zentaris
AEZS
$1.96
Share price
-1.18%
Change (1 day)
-36.88%
Change (1 year)
Categories
P/S ratio for Aeterna Zentaris (AEZS)
P/S ratio as of April 2024 (TTM): 2.13
According to Aeterna Zentaris's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.13049. At the end of 2023 the company had a P/S ratio of 2.01.
P/S ratio history for Aeterna Zentaris from 2001 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 2.01 | -26.71% |
| 2022 | 2.74 | -66.72% |
| 2021 | 8.24 | 13.32% |
| 2020 | 7.27 | -78.77% |
| 2019 | 34.2 | 1778.01% |
| 2018 | 1.82 | -95.68% |
| 2017 | 42.2 | -8.16% |
| 2016 | 46.0 | -43.41% |
| 2015 | 81.3 | -97.7% |
| 2014 | > 1000 | |
| 2013 | N/A | -100% |
| 2012 | 1.79 | -59.18% |
| 2011 | 4.39 | -15.22% |
| 2010 | 5.18 | 539.49% |
| 2009 | 0.8099 | 19.57% |
| 2008 | 0.6773 | -65.79% |
| 2007 | 1.98 | |
| 2006 | N/A | -100% |
| 2005 | 1.14 | -24.61% |
| 2004 | 1.51 | 24.21% |
| 2003 | 1.22 | -48.05% |
| 2002 | 2.34 | -67.21% |
| 2001 | 7.13 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Novartis NVS | 3.71 | 74.10% | 🇨🇭 Switzerland |
 Sanofi SNY | 2.25 | 5.61% | 🇫🇷 France |
 Bristol-Myers Squibb BMY | 2.18 | 2.09% | 🇺🇸 USA |
 Spectrum Pharmaceuticals
SPPI | 8.22 | 285.66% | 🇺🇸 USA |
 Halozyme Therapeutics HALO | 5.79 | 171.91% | 🇺🇸 USA |